Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2011 | Original Article

¹⁸F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging

Authors: Kevin London, Siobhan Cross, Ella Onikul, Luciano Dalla-Pozza, Robert Howman-Giles

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2011

Abstract

Purpose

In children with Hodgkin’s disease and non-Hodgkin’s lymphoma, the ability of ¹⁸F-fluoro-2-deoxy-D-glucose PET/CT and conventional imaging (CI) to detect malignant lesions and predict poor lesion response to therapy was assessed and compared.

Methods

A retrospective review of findings reported on PET/CT and CI was performed using a lesion-based analysis of 16 lymph node and 8 extra-nodal regions. Lesions were defined by histopathological findings or follow-up > 6 months.

Results

The study included 209 PET/CT scans with a valid CI comparator. A total of 5,014 regions (3,342 lymph node, 1,672 extra-nodal) were analysed. PET/CT performed significantly better than CI in the detection of malignant lesions with sensitivity and specificity of 95.9 and 99.7% compared to 70.1 and 99.0%, respectively. For predicting poor lesion response to therapy, PET/CT had fewer false-positive lesions than CI. The specificity for predicting poor lesion response to treatment for PET/CT was 99.2% compared to 96.9% for CI. PET/CT was the correct modality in 86% of lesions with discordant findings.

Conclusion

PET/CT is more accurate than CI in detecting malignant lesions in childhood lymphoma and in predicting poor lesion response to treatment. In lesions with discordant findings, PET/CT results are more likely to be correct.

Miller E, Metser U, Avrahami G, Dvir R, Valdman D, Sira LB, et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 2006;30(4):689–94.CrossRefPubMed

Kabickova E, Sumerauer D, Cumlivska E, Drahokoupilova E, Nekolna M, Chanova M, et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. Eur J Nucl Med Mol Imaging 2006;33(9):1025–31.CrossRefPubMed

Hermann S, Wormanns D, Pixberg M, Hunold A, Heindel W, Jürgens H, et al. Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin 2005;44(1):1–7.PubMed

Hernandez-Pampaloni M, Takalkar A, Yu JQ, Zhuang H, Alavi A. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 2006;36(6):524–31.CrossRefPubMed

Depas G, De Barsy C, Jerusalem G, Hoyoux C, Dresse MF, Fassotte MF, et al. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 2005;32(1):31–8.CrossRefPubMed

Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrous K, Younsi N, et al. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002;29(9):1155–65.CrossRefPubMed

Meany HJ, Gidvani VK, Minniti CP. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 2007;48(4):399–402.CrossRefPubMed

Lopci E, Burnelli R, Ambrosini V, Nanni C, Castellucci P, Biassoni L, et al. (18)F-FDG PET in pediatric lymphomas: a comparison with conventional imaging. Cancer Biother Radiopharm 2008;23(6):681–9.CrossRefPubMed

Riad R, Omar W, Kolb M, Hafez M, Sidhorn I, Zamzam M, et al. Role of PET/CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging 2010;37(2):319–29.CrossRefPubMed

10.

Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med 2006;144(11):850–5.PubMed

11.

Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25(5):571–8.CrossRefPubMed

12.

Friedman D, et al. AHOD0031: A phase III groupwide study of dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate risk Hodgkin disease. 2007, Children’s Oncology Group.

13.

http://faculty.vassar.edu/lowry/clin1.html.

14.

Howman-Giles R, London K, McCowage G, Graf N, Harvey J. Pulmonary inflammatory myofibroblastic tumor after Hodgkin’s lymphoma and application of PET imaging. Pediatr Surg Int 2008;24(8):947–51.CrossRefPubMed

15.

Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin’s and non-Hodgkin’s lymphoma patients: when do we really need FDG-PET? Ann Oncol 2005;16(9):1524–9.CrossRefPubMed

16.

Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma: a systematic review. J Nucl Med 2008;49(1):13–21. Comment in J Nucl Med 2008;49:9–12.CrossRefPubMed

17.

Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006;91(4):522–9.PubMed

18.

Partridge S, Timothy A, O’Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann Oncol 2000;11(10):1273–9.CrossRefPubMed

19.

Talbot JN, Haioun C, Rain JD, Meignan M, Wioland M, Misset JL, et al. [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001;38(3):193–221.CrossRefPubMed

20.

Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol 2002;81(1):20–5.CrossRefPubMed

21.

Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91(5):889–99.CrossRefPubMed

22.

Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 1998;9(10):1117–22.CrossRefPubMed

23.

Wegner EA, Barrington SF, Kingston JE, Robinson RO, Ferner RE, Taj M, et al. The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging 2005;32(1):23–30.CrossRefPubMed

24.

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Radiol 2003;58(8):575–80.CrossRefPubMed

Title: 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging
Authors: Kevin London
Siobhan Cross
Ella Onikul
Luciano Dalla-Pozza
Robert Howman-Giles
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1619-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2011

Intrathoracic splenosis: evaluation by 99mTc-labelled heat-denatured erythrocyte SPECT/CT

Interventricular delay measurement using equilibrium radionuclide angiography before resynchronization therapy should be performed outside the area of segmental wall motion abnormalities

The Clinical Audit Courses of the Committee for Accreditation of Nuclear Medicine Departments (CANMD)

Molecular imaging in cancer treatment

In vivo imaging for stem cell therapy: new developments and future challenges

AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual (7th edition)